EmpA protein, Vibrio anguillarum

Known as: EmpA metalloprotease, V. anguillarum 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2007-2017
051020072017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Heart failure (HF) is one of the most pervasive complications occurring in patients with type 2 diabetes (T2D). The risk of HF… (More)
  • figure 1
Is this relevant?
2017
2017
  • Herzkranke Diabetiker, Empagliflozin senkt, Dirk Einecke
  • CME
  • 2017
In der placebokontrollierten EMPA-REGOUTCOME-Studie mit ca. 7000 Patienten mit Diabetes und kardiovaskulären Erkrankungen… (More)
Is this relevant?
2017
2017
  • Herzkranke Diabetiker, Empagliflozin senkt, Dirk Einecke
  • CME
  • 2017
In der placebokontrollierten EMPA-REGOUTCOME-Studie mit ca. 7000 Patienten mit Diabetes und kardiovaskulären Erkrankungen… (More)
Is this relevant?
2017
2017
  • Herzkranke Diabetiker, Empagliflozin senkt, Dirk Einecke
  • CME
  • 2017
In der placebokontrollierten EMPA-REGOUTCOME-Studie mit ca. 7000 Patienten mit Diabetes und kardiovaskulären Erkrankungen… (More)
Is this relevant?
2017
2017
INTRODUCTION The first cardiovascular safety trial in the sodium-glucose co-transporter-2 (SGLT2) inhibitor drug class, the… (More)
  • table 1
  • table 2
  • table 2
  • table 3
  • table 4
Is this relevant?
2017
2017
The EMPA-REG OUTCOME study reported that a sodium glucose cotransporter-2 (SGLT2) inhibitor empagliflozin suppresses… (More)
Is this relevant?
2017
2017
In the EMPA-REG BP trial, empagliflozin significantly reduced systolic and diastolic blood pressure (SBP and DBP) compared with… (More)
Is this relevant?
Highly Cited
2016
Highly Cited
2016
The striking and unexpected relative risk reductions in cardiovascular (CV) mortality (38%), hospitalization for heart failure… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2015
2015
The EMPA-REG OUTCOME study, in which the sodium-glucose cotransporter 2 (SGLT2) inhibitor empaglifl ozin showed impressive benefi… (More)
Is this relevant?
2015
2015
EMPA-REG OUTCOME is an international, prospective, placebo-controlled clinical trial investigating the cardiovascular outcomes of… (More)
Is this relevant?